Aquestive Therapeutics Inc’s recently made public that its Chief Operating Officer Jung Cassie unloaded Company’s shares for reported $214.0 on Nov 26 ’24. In the deal valued at $4.87 per share,44 shares were sold. As a result of this transaction, Jung Cassie now holds 0 shares worth roughly $0.0.
Cantor Fitzgerald initiated its Aquestive Therapeutics Inc [AQST] rating to an Overweight in a research note published on December 17, 2024; the price target was $17. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early May with a ‘”an Outperform”‘ rating. Piper Sandler began covering AQST with “an Overweight” recommendation on April 11, 2024. Raymond James started covering the stock on March 28, 2024. It rated AQST as “an Outperform”.
Price Performance Review of AQST
On Tuesday, Aquestive Therapeutics Inc [NASDAQ:AQST] saw its stock fall -4.95% to $2.69. Over the last five days, the stock has lost -5.11%. Aquestive Therapeutics Inc shares have fallen nearly -24.44% since the year began. Nevertheless, the stocks have fallen -17.99% over the past one year. While a 52-week high of $5.80 was reached on 01/02/25, a 52-week low of $2.20 was recorded on 04/09/25. SMA at 50 days reached $2.80, while 200 days put it at $3.80.
Levels Of Support And Resistance For AQST Stock
The 24-hour chart illustrates a support level at 2.62, which if violated will result in even more drops to 2.56. On the upside, there is a resistance level at 2.78. A further resistance level may holdings at 2.88. The Relative Strength Index (RSI) on the 14-day chart is 45.31, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.47%. Stochastics %K at 64.53% indicates the stock is a holding.
